[go: up one dir, main page]

PE20120519A1 - Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida - Google Patents

Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida

Info

Publication number
PE20120519A1
PE20120519A1 PE2011001686A PE2011001686A PE20120519A1 PE 20120519 A1 PE20120519 A1 PE 20120519A1 PE 2011001686 A PE2011001686 A PE 2011001686A PE 2011001686 A PE2011001686 A PE 2011001686A PE 20120519 A1 PE20120519 A1 PE 20120519A1
Authority
PE
Peru
Prior art keywords
compound
dioxo
phenyl
dihydropyrimidin
metansulphonamide
Prior art date
Application number
PE2011001686A
Other languages
English (en)
Inventor
James J Napier
Jean-Christophe Califano
Calvin L Becker
Su Yu
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PE20120519A1 publication Critical patent/PE20120519A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO DE OBTENCION DEL COMPUESTO (E)-N-(4-(3-TERT-BUTIL-5-(2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1(2H)-IL)-2-METOXIESTIRIL)FENIL)METANSULFONAMIDA DE FORMULA (I) QUE COMPRENDE: A) REDUCIR EL COMPUESTO N-(4-((3-TERT-BUTIL-5-(2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1(2H)-IL)-2-METOXIFENIL)ETINIL)FENIL)METANSULFONAMIDA DE FORMULA (6) EMPLEANDO UN SILANO TAL COMO TRIETILSILANO, FENILSILANO, HEXAMETILDISILANO, ENTRE OTROS, Y EN PRESENCIA DE UN CATALIZADOR DE PALADIO Y UN SOLVENTE TAL COMO DIMETILFORMAMIDA, DIMETILACETAMIDA, ENTRE OTROS. DONDE EL COMPUESTO (6) SE OBTIENE HACIENDO REACCIONAR EL COMPUESTO 1-(3-TERT-BUTIL-5-ETINIL-4-METOXIFENIL)PIRIMIDIN-2,4(1H,3H)-DIONA CON UNO DE LOS COMPUESTOS SELECCIONADOS DE N-(4-YODOFENIL)METANSULFONAMIDA, N-(4-BROMOFENIL)METANSULFONAMIDA, N-(4-CLOROFENIL)METANSULFONAMIDA, ENTRE OTROS, EN PRESENCIA DE UNA BASE Y UN SOLVENTE. DICHO COMPUESTO DE FORMULA (I) ES UTIL PARA INHIBIR EL VIRUS DE LA HEPATITIS C
PE2011001686A 2009-03-24 2010-03-24 Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida PE20120519A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16270509P 2009-03-24 2009-03-24
US31671310P 2010-03-23 2010-03-23

Publications (1)

Publication Number Publication Date
PE20120519A1 true PE20120519A1 (es) 2012-06-03

Family

ID=42136100

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001686A PE20120519A1 (es) 2009-03-24 2010-03-24 Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida

Country Status (23)

Country Link
EP (1) EP2411372B1 (es)
JP (1) JP5744003B2 (es)
KR (1) KR101665955B1 (es)
CN (1) CN102361858B (es)
AU (1) AU2010229975B2 (es)
BR (1) BRPI1009854A2 (es)
CA (1) CA2753825C (es)
CL (1) CL2011002278A1 (es)
CO (1) CO6450678A2 (es)
CR (1) CR20110524A (es)
DO (1) DOP2011000297A (es)
EC (1) ECSP11011415A (es)
ES (1) ES2488821T3 (es)
GT (1) GT201100241A (es)
IL (1) IL214858A (es)
MX (1) MX2011010049A (es)
MY (1) MY169288A (es)
NZ (1) NZ594923A (es)
PE (1) PE20120519A1 (es)
RU (1) RU2524573C2 (es)
SG (1) SG174211A1 (es)
WO (1) WO2010111348A1 (es)
ZA (1) ZA201106511B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
BR112013001138A2 (pt) 2010-07-16 2016-07-05 Abbvie Inc ligantes de fosfina para reações catalíticas
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
AU2011278927B2 (en) 2010-07-16 2015-05-21 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
TWI558400B (zh) * 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021624A1 (en) * 1999-09-20 2001-03-29 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
AU779412B2 (en) * 1999-09-22 2005-01-20 Sanofi-Aventis Deutschland Gmbh 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
DE10051981A1 (de) * 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
EP2038253A1 (en) * 2006-05-30 2009-03-25 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
MX2010002904A (es) * 2007-09-17 2010-06-02 Abbott Lab N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
RU2543620C2 (ru) * 2007-09-17 2015-03-10 Эббви Бахамаз Лтд. Производные урацила или тимина для лечения гепатита с
ES2383273T3 (es) * 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos

Also Published As

Publication number Publication date
NZ594923A (en) 2013-11-29
RU2011142757A (ru) 2013-04-27
CL2011002278A1 (es) 2012-03-09
KR20110137372A (ko) 2011-12-22
IL214858A (en) 2015-05-31
CN102361858A (zh) 2012-02-22
EP2411372A1 (en) 2012-02-01
MX2011010049A (es) 2011-10-11
CN102361858B (zh) 2014-07-23
ECSP11011415A (es) 2011-11-30
CR20110524A (es) 2012-01-19
HK1166798A1 (en) 2012-11-09
EP2411372B1 (en) 2014-07-23
AU2010229975A1 (en) 2011-09-29
CA2753825C (en) 2017-10-17
GT201100241A (es) 2015-08-19
DOP2011000297A (es) 2011-10-15
AU2010229975B2 (en) 2015-05-21
IL214858A0 (en) 2011-11-30
SG174211A1 (en) 2011-10-28
CA2753825A1 (en) 2010-09-30
BRPI1009854A2 (pt) 2015-08-25
MY169288A (en) 2019-03-21
RU2524573C2 (ru) 2014-07-27
KR101665955B1 (ko) 2016-10-13
WO2010111348A1 (en) 2010-09-30
JP5744003B2 (ja) 2015-07-01
JP2012521990A (ja) 2012-09-20
ES2488821T3 (es) 2014-08-29
ZA201106511B (en) 2012-05-30
CO6450678A2 (es) 2012-05-31

Similar Documents

Publication Publication Date Title
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20120519A1 (es) Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
SV2009003157A (es) Profarmaco de compuesto de cinamida
NZ596538A (en) Haloalkyl heteroaryl benzamide compounds
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AR065649A1 (es) Dionas ciclicas herbicidamente activas, procesos de obtencion y composiciones.
PE20090326A1 (es) Compuestos heterociclos como inhibidores de erk
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20140923A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200900676A1 (ru) Ингибиторы вируса гепатита с
PE20141996A1 (es) Compuestos con actividad nematicida
RU2015103515A (ru) Производное соединение сложного эфира 2-аминоникотиновой кислоты и бактерицид, содержащий то же самое в качестве активного ингредиента
MA38540A1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
PE20140934A1 (es) Derivados de pirazol
PE20100487A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable

Legal Events

Date Code Title Description
FG Grant, registration